The tools behind the takeaway.

The standard growth-adjacency framework measures the wrong kind of distance — and that error explains a lot of failed growth initiatives.

Proprietary capability often never leaves the division that built it. The constraint isn't the technology — it's the missing transfer framework.

A revenue decline can reverse itself or be permanent — each needs an opposite response. There's a documented way to tell which.

Most market reads stop at size and growth. That's two questions of several — and stopping there often gets the call wrong.

Before entering an adjacency, the real question isn't whether you can. It's whether your assets hold up once you're in.

Catching change early through weak signals is well-studied — and still routinely ignored, because reading it right is genuinely hard.

Most channels weren't designed. They were assembled quickly out of necessity, and never redesigned once the necessity passed.

Broad-launch entries rarely survive. A foundational 1991 book explains why narrow works better — and why it's hard to follow.

Three Horizons balances today against tomorrow, but not how to find Horizon 3 — those opportunities don't show up in H1/H2 data.

Drug R&D has gotten scientifically better and economically worse for sixty years. Treating it as a line, not a loop, is part of why.

A plausibleor what looks like a reasonable answer usually shows up in the first day or two. Having the discipline not to stop there--is the real work.